Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner‐type interstitial cystitis: Real‐world data postofficial approval in Japan
International Journal of Urology · 2024
DOI: 10.1111/iju.15320 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Urology, 2024. Verfasst von Yoshiyuki Akiyama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Cystitis, Interstitial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan Society for the Promotion of Science (JSPS).
Abstract (Originalsprache)
Objectives
To examine real‐world data regarding intravesical dimethyl sulfoxide (DMSO) therapy after official approval as a treatment for Hunner‐type interstitial cystitis (HIC) in Japan.
Methods
This single institution, retrospective observational study was conducted between 2021 and 2022 to evaluate the outcomes of 30 patients with refractory HIC who received intravesical DMSO therapy according to the approved standardized regimen: administration of DMSO every 2 weeks for a total of 12 weeks. Treatment outcomes were evaluated using a 7‐graded global response assessment scale, O'Leary and Sant's symptom and problem indices (OSSI/OSPI), the overactive bladder symptom score (OABSS), an 11‐point pain intensity numerical rating scale, quality of life (QOL) score, and frequency volume chart variables. Related complications were also documented.
Results
The response rates at 2, 4, 6, 8, 10, and 12 weeks were 36.7%, 43.3%, 53.3%, 60.0%, 70.0%, and 70.0%, respectively. Compared with baseline, OSSI/OSPI, pain intensity, urinary frequency, and the QOL score improved significantly from 4 weeks of treatment. The OABSS score and functional bladder capacity also showed a tendency toward moderate improvement, but the difference was not significant. The mean duration of symptom relapse after termination of treatment was 6.4 ± 3.9 months. No patients discontinued treatment due to adverse events, although acute bladder irritation during infusion was noted in 21 patients (70%), which disappeared within 3 days.
Conclusions
This study verifies the safety, moderately durable efficacy, and tolerability of the standard intravesical treatment with DMSO for HIC in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Urology, New Tokyo Hospital, Matsudo, Chiba, Japan.
- Department of Urology, Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan.
- Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
- Department of Interstitial Cystitis Medicine, Kyorin University School of Medicine, Tokyo, Japan.
ORCID-Profile: Yusuke Sato, Taketo Kawai
Förderung
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (JSPS)
Zitieren
APA
Akiyama, Y., Niimi, A., Nomiya, A., Taguchi, S., Yamada, Y., Sato, Y., Kawai, T., Yamada, D., Kume, H., & Homma, Y. (2024). Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner‐type interstitial cystitis: Real‐world data postofficial approval in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15320
Vancouver
Akiyama Y, Niimi A, Nomiya A, Taguchi S, Yamada Y, Sato Y, et al. Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner‐type interstitial cystitis: Real‐world data postofficial approval in Japan. International Journal of Urology. 2024. doi:10.1111/iju.15320
BibTeX
@article{Akiyama2024,
author = {Akiyama, Yoshiyuki and Niimi, Aya and Nomiya, Akira and Taguchi, Satoru and Yamada, Yuta and Sato, Yusuke and Kawai, Taketo and Yamada, Daisuke and Kume, Haruki and Homma, Yukio},
title = {Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner‐type interstitial cystitis: Real‐world data postofficial approval in Japan},
journal = {International Journal of Urology},
year = {2024},
doi = {10.1111/iju.15320}
}
EUVIMED